P9-8 Retrospective analysis of the safety and effectiveness of immune checkpoint inhibitors in mucosal melanoma patients

Abstract

In Japanese populations, the primary sites of melanoma are cutaneous (%) and mucosal (8%). Mucosal melanoma is an aggressive malignancy with a poor response to immune checkpoint inhibitor compared with cutaneous melanoma.We reviewed the safety and effectiveness of immune checkpoint inhibitors in mucosal melanomapatients.